Groundbreaking CD19 Binders For Immunotherapy Innovation
Pioneering the Future with State-of-the-Art Binder Discovery
Our groundbreaking binder discovery is a result of our exclusive research collaboration with the University of Pennsylvania. This partnership led to two anti-CD19 binders, one of which is called DS191, that rival those available in the commercial market.
Unleashing the Powerful Combination of Novel Binders and the KIR-CAR Platform
Harnessing the power of our DS191 binder and multi-chain KIR-CAR construct, we’ve crafted the revolutionary SynKIR™-310, our product candidate for patients battling relapsed or refractory diffuse large B cell lymphoma (DLBCL) post-CAR T therapy.
Advancing Precision Medicine Together
True innovation is a collective endeavor. Verismo Therapeutics welcomes the opportunity to collaborate with other organizations to enable new treatments through our new CD19 binders.